Abatacept [abatacept]
topical
73
- Terms
-
fúzovaná molekula CTLA4-Ig
Orencia
-
Belatacept
BMS 188667
BMS-188667
BMS-224818
BMS224818
CTLA-4-Ig
CTLA4-Fc
CTLA4-Ig
CTLA4-Ig Immunoconjugate
Cytotoxic T Lymphocyte-Associated Antigen 4-Immunoglobulin
LEA29Y
Nulojix
Orencia
Persistent link
https://www.medvik.cz/link/D000069594
Definition
A fusion protein immunoconjugate of the extracellular domain of CTLA4 and the Fc domain of human IgG1. It functions as a T-cell co-stimulation blocker that inhibits TNF-ALPHA and prevents the activation of T-LYMPHOCYTES. It is used in the treatment of RHEUMATOID ARTHRITIS.
- DUI
- D000069594 MeSH Browser
- CUI
- M0442852
- RN
- 7D0YB67S97
- History note
- 2016 (2002)
- Public note
- 2016; ABATACEPT was indexed under IMMUNOCONJUGATES 2002-2015
Allowable subheadings
- AD
- administration & dosage 16
- AE
- adverse effects 10
- AN
- analysis 0
- BI
- biosynthesis 0
- BL
- blood 0
- CF
- cerebrospinal fluid 0
- CH
- chemistry 0
- CL
- classification 0
- DE
- drug effects 0
- EC
- economics 0
- GE
- genetics 0
- HI
- history 0
- IM
- immunology 1
- IP
- isolation & purification 0
- ME
- metabolism 0
- PK
- pharmacokinetics 0
- PD
- pharmacology 6
- PH
- physiology 0
- PO
- poisoning 0
- RE
- radiation effects 0
- TU
- therapeutic use 22
- TO
- toxicity 0
- UL
- ultrastructure 0
- UR
- urine 0
...
Occurrences in Medvik records
D
Chemicals and Drugs